Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Rituximab Is Highly Effective In The Treatment Of Patients With Autoimmune Blood Cytopenias, Particularly When It Is Followed By a Post-Induction Consolidation / Maintenance Phase

Argiris Symeonidis, MD, PhD, Nikolaos Giannakoulas, Eleni Kapsali, Anna Christoforidou, Zoe Topouzoglou, Polyxeni Lampropoulou, MD, Evangelia Tzouvara, Nikolaos Anagnostopoulos, MD, Dimitris Margaritis, George Vassilopoulos, MD, PhD, Evangelos Briasoulis, Alexandra Kouraklis

Blood (2013) 122 (21): 3539.

https://doi.org/10.1182/blood.V122.21.3539.3539

Published: 2013

Journal Articles

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Athanasios Anagnostopoulos, MD, Steven P. Treon, MD, Konstantinos Zervas, MD, Andrew Branagan, MD, Dimitra Gika, Athanasios Zomas, MD, Marie Christine Kyrtsonis, MD, Amalia Vassou, MD, Nikolaos Anagnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3485.

https://doi.org/10.1182/blood.V106.11.3485.3485

Published: 2005

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Evangelos Terpos, MD, PhD, Athanasios Anagnostopoulos, MD, PhD, Efstathios Kastritis, MD, Athanasios Zomas, MD, Christos Poziopoulos, MD, Nikolaos Anagnostopoulos, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 363.

https://doi.org/10.1182/blood.V106.11.363.363

Published: 2005

Journal Articles

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Meletios A. Dimopoulos, MD, Panagiotis Repoussis, MD, Evangelos Terpos, MD, Maria Christina Kyrtsonis, MD, Athanasios Zomas, MD, Eirini Katodritou, MD, Souzana Delibasi, MD, Amalia Vassou, MD, Athanasios Anagnostopoulos, MD, Anastasia Pouli, MD, Konstantinos Zervas, MD, Dimitrios Margaritis, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD

Blood (2004) 104 (11): 1482.

https://doi.org/10.1182/blood.V104.11.1482.1482

Published: 2004

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Maria Christina Kyrtsonis, MD, Constantinos Tsatalas, MD, Garyfallia Kokkini, MD, Panagiotis Repoussis, MD, Athanasios Zomas, MD, Argiris Symeonidis, MD, Evridiki Michali, MD, Athanasios Anagnostopoulos, MD, Nikolaos Anagnostopoulos, MD, Theophanis Economopoulos, MD, Gerasimos Pangalis, MD

Blood (2004) 104 (11): 752.

https://doi.org/10.1182/blood.V104.11.752.752

Published: 2004

Journal Articles

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Athanasios Anagnostopoulos, MD, Dimitra Gika, Argiris Symeonidis, MD, Konstantinos Zervas, MD, Anastasia Pouli, MD, Panagiotis Repoussis, MD, Vassiliki Grigoraki, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2004) 104 (11): 4847.

https://doi.org/10.1182/blood.V104.11.4847.4847

Published: 2004

NARROW

Rituximab Is Highly Effective In The Treatment Of Patients With Autoimmune Blood Cytopenias, Particularly When It Is Followed By a Post-Induction Consolidation / Maintenance Phase

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Email alerts

ASH Publications

American Society of Hematology

Rituximab Is Highly Effective In The Treatment Of Patients With Autoimmune Blood Cytopenias, Particularly When It Is Followed By a Post-Induction Consolidation / Maintenance Phase

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only